All In Biotech

Drug Trial Radar · NCT04770220

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

325

Actual

Start

May 19, 2021

Primary completion

May 29, 2024

Study completion Jul 29, 2024

Sponsor

Lead sponsor
Alzheon Inc.Industry
Sponsor type
Industry
Collaborators
National Institute on Aging (NIA)
First posted
Feb 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.

Conditions

  • Early Alzheimer's Disease

Interventions

  • Experimental: ALZ-801Drug

    ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID

  • Placebo Comparator: PlaceboDrug

    Placebo tablet BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Cognitive Efficacy Endpoint (ADAS-Cog13)Time frame: Baseline to Week 78
  2. Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)Time frame: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Locations

95 sites in 9 countries. Site status is shown where the registry gives one.

  • Xenoscience

    Phoenix, Arizona

  • CCT Research

    Scottsdale, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • ATP Clinical Research

    Costa Mesa, California

  • Tilda Research

    Irvine, California

  • UCSD Shiley-Marcos Alzheimer's Disease Research Center

    La Jolla, California

  • Torrance Clinical Research Institute

    Lomita, California

  • Collaborative NeuroScience Network LLC

    Long Beach, California

  • Stanford University

    Palo Alto, California

  • SC3 Research Group

    Pasadena, California

  • Sutter Health

    Sacramento, California

  • JEM Research Institute, Headlands Site

    Atlantis, Florida

  • Bradenton Research Center

    Bradenton, Florida

  • Galiz Research

    Hialeah, Florida

  • Alphab Global Research

    Jupiter, Florida

  • Charter Research

    Lady Lake, Florida

  • K2 Medical Research, LLC

    Maitland, Florida

  • Miami Jewish Health

    Miami, Florida

  • Y & L Advance Health Care, Inc /DBA Elite Clinical Research

    Miami, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Aqualane Clinical Research

    Naples, Florida

  • Charter Research

    Orlando, Florida

  • Headlands Research Orlando

    Orlando, Florida

  • Advanced Research Consultants

    Palm Beach Gardens, Florida

  • Quantum CNS Clinical Research

    Pompano Beach, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • ALZ Research and Treatment Center (A.R.T.C.)

    Stuart, Florida

  • ALZ Research and Treatment Center (A.R.T.C.)

    Wellington, Florida

  • Premiere Research Institute

    West Palm Beach, Florida

  • Columbus Memory Center

    Columbus, Georgia

  • Sandhill Research, LLC

    Decatur, Georgia

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • Louisiana State University Health Sciences Center (LSUHSC)

    Shreveport, Louisiana

  • Headlands Research Eastern MA

    Plymouth, Massachusetts

  • WR-CRCN

    Las Vegas, Nevada

  • Advanced Memory Research Center

    Toms River, New Jersey

  • Neurological Associates of Albany

    Albany, New York

  • NYU Alzheimer's Disease Research Center

    New York, New York

  • Kline Institute for Psychiatric Research

    Orangeburg, New York

  • University of Rochester Medical Center

    Rochester, New York

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.